Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 18/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 7/20 | 0.43 |
| ▸ | EGLN3 | Q9H6Z9 | 7/20 | 0.43 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.42 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.41 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1641077 | 0.87 | EGLN1 (0.60) | EGLN1EGLN2EGLN3CYSLTR2OGFOD1 | |
| SCHEMBL1642978 | 0.82 | EGLN1 (0.43) | EGLN1EGLN2EGLN3OGFOD1HIF1AN | |
| SCHEMBL1643005 | 0.82 | EGLN1 (0.46) | EGLN1EGLN2EGLN3CYSLTR2 | |
| SCHEMBL1642647 | 0.80 | EGLN1 (0.49) | EGLN1EGLN2EGLN3OGFOD1HIF1AN | |
| SCHEMBL1641307 | 0.79 | EGLN1 (0.56) | EGLN1EGLN2EGLN3OGFOD1HIF1AN | |
| SCHEMBL1642544 | 0.76 | EGLN1 (0.46) | EGLN1EGLN2EGLN3OGFOD1HIF1AN | |
| SCHEMBL1642112 | 0.76 | EGLN3 (0.45) | EGLN1EGLN2EGLN3CYSLTR2 | |
| SCHEMBL1642217 | 0.75 | EGLN1 (0.67) | EGLN1EGLN2EGLN3OGFOD1HIF1AN | |
| SCHEMBL1641845 | 0.75 | EGLN1 (0.67) | EGLN1EGLN2EGLN3OGFOD1HIF1AN | |
| SCHEMBL1641949 | 0.75 | EGLN1 (0.67) | EGLN1EGLN2EGLN3OGFOD1HIF1AN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | EGLN1 6/4885EGLN2 2/4885EGLN3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.